ANDA 76354, held by Rising Pharmaceuticals. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 76354 (Tizanidine Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Mar 28, 2003, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2003 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Dec 13, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 13, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 22, 2010 | Supplement 6Labeling | Approved | None posted |
| Nov 14, 2008 | Supplement 5Labeling | Approved | None posted |
| Mar 28, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters